Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders using its proprietary PEP™ platform [3] - The company is advancing a pipeline of novel candidates targeting endocrine and metabolic disorders with clinically validated targets, established regulatory endpoints, significant unmet medical needs, and large market opportunities [3] - Key pipeline includes MBX 2109 (Phase 2 for chronic hypoparathyroidism), MBX 1416 (Phase 1 for post-bariatric hypoglycemia), and MBX 4291 (obesity portfolio) [3] Upcoming Events - The company's President and CEO, Kent Hawryluk, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 2:15 PM Pacific Time [1] - MBX Biosciences will participate in 1-on-1 investor meetings during the conference [1] - A live webcast of the presentation will be available on the company's investor website, with a replay accessible approximately two hours post-event and archived for 30 days [2]
MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference